TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 305 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $430,390 | +41.1% | 27,821 | +43.3% | 0.04% | +52.0% |
| Q2 2023 | $305,010 | -12.9% | 19,415 | -8.6% | 0.02% | -21.9% |
| Q1 2023 | $350,168 | +73.4% | 21,248 | +64.2% | 0.03% | +60.0% |
| Q4 2022 | $201,925 | -37.7% | 12,944 | -48.2% | 0.02% | -41.2% |
| Q3 2022 | $324,000 | +105.1% | 24,985 | +120.8% | 0.03% | +112.5% |
| Q2 2022 | $158,000 | -46.1% | 11,314 | -44.6% | 0.02% | -38.5% |
| Q1 2022 | $293,000 | +23.6% | 20,424 | +17.8% | 0.03% | +30.0% |
| Q4 2021 | $237,000 | -16.8% | 17,338 | -0.4% | 0.02% | -23.1% |
| Q3 2021 | $285,000 | +7.5% | 17,400 | +10.6% | 0.03% | +4.0% |
| Q2 2021 | $265,000 | -15.1% | 15,730 | -7.9% | 0.02% | -19.4% |
| Q1 2021 | $312,000 | +16.4% | 17,073 | +15.9% | 0.03% | 0.0% |
| Q4 2020 | $268,000 | -8.8% | 14,732 | -10.5% | 0.03% | -20.5% |
| Q3 2020 | $294,000 | +12.2% | 16,452 | +12.6% | 0.04% | +5.4% |
| Q2 2020 | $262,000 | – | 14,610 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |